16(17)-EpDPE MF: C22H32O3
MW: 344.5
The DHA homolog of 14(15)-EpETrE, significant to CYP450 metabolism.

16(17)-EpDPE

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 129ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Application: 16(17)-EpDPE is the DHA homolog of 14(15)-EpETrE, significant to CYP450 metabolism
Masse Moléculaire: 344.5
Formule Moléculaire: C22H32O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as 14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been little studied relative to arachidonate epoxygenase metabolites. 16(17)-EpDPE is the DHA homolog of 14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of docosahexaenoic acid (DHA). The EDHF activity of 16(17)-EpDPE has not yet been determined and the epoxygenase metabolites of DHA have also been detected in a murine inflammation model.


Références

1 Chataigneau, T., Félétou, M., Duhault, J., et al. Epoxyeicosatrienoic acids, potassium channel blockers, and endothelium-dependent hyperpolarization in the guinea-pig carotid artery. Br J Pharmacol 123 574-580 (1998). 2 Fisslthaler, B., Popp, R., Kiss, L., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 493-497 (1999). 3 Baron, A., Frieden, M., Bény, J. Epoxyeicosatrienoic acids activate a high-conductance, Ca2+-dependent K+ channel on pig coronary artery endothelial cells. J Physiol 504 537-543 (1997). 4 Serhan, C.N., Hong, S., Gronert, K., et al. Resolvins: A family of bioactive products of ω-3 fatty acid transformation circuits by aspirin treatment that counter proinflammation signals. J Exp Med 196(8) 1025-1037 (2002).

Formulation :
A solution in ethanol
État Physique :
Liquid
STOCKAGE :
Store at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
35020781
SMILES :
CC/C=C\C[[email protected]@H]1[[email protected]@H](O1)C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O

Télécharger la Fiche de Sécurité/ SDS (MSDS)

CERTIFICAT D'ANALYSE

Pour une bonne lecture, Adobe Acrobat Reader est requis,
imprimer et commenter les documents PDF

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 115ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. est leader mondial dans le développement de produits pour la recherche biomédicale. Contactez-nous au 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. Tous Droits Réservés. "Santa Cruz Biotechnology", et le logo Santa Cruz Biotechnology, Inc., "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", le logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", et "EZ Touch" sont des marques déposées de Santa Cruz Biotechnology, Inc.
Toutes les marques sont la propriété de leurs propriétaires respectifs.